Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Homebuilding stocks are in for a nasty surprise

"You can't believe how screwed up things are down here… " This weekend, I met up with a real estate expert, M, from South Florida. M specializes in REO. REO stands for "Real Estate Owned." Banks lend money to homeowners. Sometimes homeowners don't make their int...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...

Krill oil boom is real

There’s a new type of oil that’s causing a major stir in the markets. This oil boom has nothing to do with crude oil or energy though. But it still has the potential to be just as profitable. I’m talking about krill oil. ...

5 Ways Tech Startups can Compete with the Industry Leaders

It is a common thing for any established industry to be dominated by several large companies. There are eBay and Amazon for eCommerce, Facebook and Snapchat for social media, Uber and Lyft for transportation, etc. Beating such competitors is a tough challenge every ...

A steady diet of plastic

People eating fish are advised to watch carefully for bones, but how about tiny pieces of plastic? For years it has been known that plastic breaks down into microscopic particles that are consumed by shellfish, fish and mammals higher up the food chain, presentin...

The Hottest Tech Sector Of 2020: Interview With Sayan Navaratnam

Uber transformed transportation when it spent a fortune turning ride-sharing into a mainstream mode of transportation. But the 2.0 version of ride-sharing is where the real disruption begins. It fixes everything that's wrong and latches onto a mega-trend the giants shouldn't h...

Akazoo Is Trading for a Song (for Now)

The disruptive forces of the Internet, technology, streaming and OTT [over-the-top] services are well known. They have not only created new industries but forced existing entities to change their business models in order to survive. This is particularly true of the media ...
1 2